SHR-A1811 & Apartinib
Phase 2Small molecule
SHR-A1811 & Apartinib is one of 35 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Gastroesophageal Junction Adenocarcinoma
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Beyfortus
BeiGenePhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-A1811 & Apartinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- YYunpeng Liu